Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C9H11NO3 |
| Molecular Weight | 181.1885 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CNCC(=O)C1=CC=C(O)C(O)=C1
InChI
InChIKey=PZMVOUYYNKPMSI-UHFFFAOYSA-N
InChI=1S/C9H11NO3/c1-10-5-9(13)6-2-3-7(11)8(12)4-6/h2-4,10-12H,5H2,1H3
| Molecular Formula | C9H11NO3 |
| Molecular Weight | 181.1885 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Adrenalone is a keton form of the natural substrate epinephrine. Adrenalone is evidently formed in vivo by hydrolytic cleavage of the diester by esterases. It is an adrenergic receptor agonist. Adrenalone inhibits the norepinephrine synthesis and dopamine beta oxidase. It is known to have very weak sympathomimetic activity when compared to adrenaline. Adrenalone has the high radioprotective effect. It is a topical nasal decongestant. Adrenalone has hemostatic, sympathomimetic and vasoconstrictor therapeutic functions.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL3102 Sources: https://www.ncbi.nlm.nih.gov/pubmed/13899905 |
|||
Target ID: Norepinephrine synthesis Sources: https://www.ncbi.nlm.nih.gov/pubmed/13899911 |
|||
Target ID: CHEMBL2095203 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Preventing | Unknown Approved UseUnknown |
|||
| Primary | Stryphnon Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Radiation protective effect of beta-ketoanalogs of hydroxyphenyl ethanolamines]. | 1998-02-19 |
|
| Modified syntheses of dopamine-4-sulfate, epinephrine-3-sulfate, and norepinephrine-3-sulfate: determination of the position of the sulfate group by 1H-NMR spectroscopy. | 1988-08 |
|
| Analysis of USP epinephrine injections for potency, impurities, degradation products, and d-enantiomer by liquid chromatography, using ultraviolet and electrochemical detectors. | 1985-03-01 |
|
| Improved Delivery Through Biological Membranes. XVII. A Site-Specific Chemical Delivery System as a Short-Acting Mydriatic Agent. | 1984-07 |
|
| Formation of adrenaline in the iris-ciliary body from adrenalone diesters. | 1984-06 |
|
| Electron spin resonance-spin stabilization of semiquinones produced during oxidation of epinephrine and its analogues. | 1984-01-10 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9467647
Mice: 50-150 mumol/kg
Route of Administration:
Unknown
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21885739
Substrate uptake by norepinephrine transporter was reduced to 99% (27%) at 10-uM (100-uM) concentrations of adrenalone; the half maximal inhibitory concentration (IC50) value of adrenalone was 36.9 uM.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:21:02 GMT 2025
by
admin
on
Mon Mar 31 18:21:02 GMT 2025
|
| Record UNII |
EGU41QL329
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
A01AD06
Created by
admin on Mon Mar 31 18:21:02 GMT 2025 , Edited by admin on Mon Mar 31 18:21:02 GMT 2025
|
||
|
WHO-ATC |
B02BC05
Created by
admin on Mon Mar 31 18:21:02 GMT 2025 , Edited by admin on Mon Mar 31 18:21:02 GMT 2025
|
||
|
WHO-VATC |
QB02BC05
Created by
admin on Mon Mar 31 18:21:02 GMT 2025 , Edited by admin on Mon Mar 31 18:21:02 GMT 2025
|
||
|
WHO-VATC |
QA01AD06
Created by
admin on Mon Mar 31 18:21:02 GMT 2025 , Edited by admin on Mon Mar 31 18:21:02 GMT 2025
|
||
|
NCI_THESAURUS |
C87053
Created by
admin on Mon Mar 31 18:21:02 GMT 2025 , Edited by admin on Mon Mar 31 18:21:02 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB05279MIG
Created by
admin on Mon Mar 31 18:21:02 GMT 2025 , Edited by admin on Mon Mar 31 18:21:02 GMT 2025
|
PRIMARY | |||
|
7436
Created by
admin on Mon Mar 31 18:21:02 GMT 2025 , Edited by admin on Mon Mar 31 18:21:02 GMT 2025
|
PRIMARY | |||
|
99-45-6
Created by
admin on Mon Mar 31 18:21:02 GMT 2025 , Edited by admin on Mon Mar 31 18:21:02 GMT 2025
|
PRIMARY | |||
|
DTXSID5048710
Created by
admin on Mon Mar 31 18:21:02 GMT 2025 , Edited by admin on Mon Mar 31 18:21:02 GMT 2025
|
PRIMARY | |||
|
17073
Created by
admin on Mon Mar 31 18:21:02 GMT 2025 , Edited by admin on Mon Mar 31 18:21:02 GMT 2025
|
PRIMARY | RxNorm | ||
|
EGU41QL329
Created by
admin on Mon Mar 31 18:21:02 GMT 2025 , Edited by admin on Mon Mar 31 18:21:02 GMT 2025
|
PRIMARY | |||
|
m1430
Created by
admin on Mon Mar 31 18:21:02 GMT 2025 , Edited by admin on Mon Mar 31 18:21:02 GMT 2025
|
PRIMARY | Merck Index | ||
|
Adrenalone
Created by
admin on Mon Mar 31 18:21:02 GMT 2025 , Edited by admin on Mon Mar 31 18:21:02 GMT 2025
|
PRIMARY | |||
|
CHEMBL2103996
Created by
admin on Mon Mar 31 18:21:02 GMT 2025 , Edited by admin on Mon Mar 31 18:21:02 GMT 2025
|
PRIMARY | |||
|
DB13394
Created by
admin on Mon Mar 31 18:21:02 GMT 2025 , Edited by admin on Mon Mar 31 18:21:02 GMT 2025
|
PRIMARY | |||
|
100000087688
Created by
admin on Mon Mar 31 18:21:02 GMT 2025 , Edited by admin on Mon Mar 31 18:21:02 GMT 2025
|
PRIMARY | |||
|
243611
Created by
admin on Mon Mar 31 18:21:02 GMT 2025 , Edited by admin on Mon Mar 31 18:21:02 GMT 2025
|
PRIMARY | |||
|
3174
Created by
admin on Mon Mar 31 18:21:02 GMT 2025 , Edited by admin on Mon Mar 31 18:21:02 GMT 2025
|
PRIMARY | |||
|
C81339
Created by
admin on Mon Mar 31 18:21:02 GMT 2025 , Edited by admin on Mon Mar 31 18:21:02 GMT 2025
|
PRIMARY | |||
|
202-756-9
Created by
admin on Mon Mar 31 18:21:02 GMT 2025 , Edited by admin on Mon Mar 31 18:21:02 GMT 2025
|
PRIMARY | |||
|
96
Created by
admin on Mon Mar 31 18:21:02 GMT 2025 , Edited by admin on Mon Mar 31 18:21:02 GMT 2025
|
PRIMARY | |||
|
C040224
Created by
admin on Mon Mar 31 18:21:02 GMT 2025 , Edited by admin on Mon Mar 31 18:21:02 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (TLC)
USP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|